PMID- 24427354
OWN - NLM
STAT- MEDLINE
DCOM- 20140905
LR  - 20211021
IS  - 1936-2625 (Electronic)
IS  - 1936-2625 (Linking)
VI  - 7
IP  - 1
DP  - 2014
TI  - Evaluation of the progesterone receptor status in breast cancer using three 
      different antibodies: a comparison by Allred score system.
PG  - 331-9
AB  - Breast cancer (BC) hormonal receptors status is assessed by immunohistochemistry 
      (IHC), a specific, sensitive, and accessible method that guide breast cancer 
      treatment. In this study, we evaluated progesterone receptor (PR) expression in 
      53 BC cases using 3 anti-PgR antibodies (AB): monoclonal (SP42 and PgR636) and 
      polyclonal ab62621. Primary BC cases (with signed informed consent) were used to 
      generate tissue microarray platforms, where PR expression was accessed by IHC and 
      evaluated by the Allred score. Categorical and quantitative data are shown in 
      percentage and mean, respectively. Concordance (CON) and correlation among ABs 
      were analyzed by Kappa factor (Kappa), Spearman's correlation coefficient (rho) or 
      intraclass correlation coefficient. Staining patterns of each AB were compared by 
      paired T-Test. We noted poor CON and Kappa between ab62621 vs SP42 (CON=64.1%; 
      Kappa=0.247), and ab62621 vs PgR636 (CON=62.3%; Kappa=0.204), but higher CON between SP42 
      vs PgR636 (CON 90.6%; Kappa=0.738). Data were corroborated by Mc Nemar statistical 
      test (p=0.019, p=0.014 and p>0.05, respectively). Regarding staining intensity 
      (SI) among PgR+ samples, we found higher proportion of weak staining and lower SI 
      for ab62621 (48.3%; mean IS=1.6), when compared to SP42 (20.0%, mean IS=2.1, 
      T-test p<0.01) and PgR636 (2.3, 21.9%, T-test p<0.01). Within the entire sample, 
      similar results were observed following rho: SP42 vs PgR636 (rho=0.8103); ab62621 vs 
      SP42 (rho=0.3524); ab62621 vs PgR636 (rho=0.4075). As for proportion of stained cells 
      and proportion score (PS), among PgR+ samples, the mean values for ab62621 
      (75.4%; 4.8) were significantly higher than those of SP42 (56.3%, 4.3; T-test 
      p<0.01) and RPG636 (60.1%; 4.2; T-test p<0.01). Similar data were found after 
      analyzing PS for the entire sample: SP42 vs PgR636 (rho=0.8588); SP42 vs ab62621 
      (rho=0.4832); RPG636 vs ab62621 (rho=0.4050). Our data indicate that anti-PgR 
      monoclonal ABs, PgR636 and SP42, are, unlike ab62621, equally suitable to test BC 
      PgR status by IHC due to their higher accuracy. Therefore, we suggest their 
      clinical use during BC diagnosis; thus, enabling more precise therapeutic 
      decisions to treat BC.
FAU - Daltoe, Renata Dalmaschio
AU  - Daltoe RD
AD  - Biotechnology Program/RENORBIO, Federal University of Espirito Santo Brazil ; 
      Department of Pharmacy and Nutrition, Federal University of Espirito Santo 
      Brazil.
FAU - Madeira, Klesia Pirola
AU  - Madeira KP
AD  - Biotechnology Program/RENORBIO, Federal University of Espirito Santo Brazil.
FAU - de Carvalho, Alex Assis
AU  - de Carvalho AA
AD  - Department of Pathology, Federal University of Espirito Santo Brazil.
FAU - de Rezende, Lucas Cunha Dias
AU  - de Rezende LC
AD  - Biotechnology Program/RENORBIO, Federal University of Espirito Santo Brazil.
FAU - Silva, Ian Victor
AU  - Silva IV
AD  - Department of Morphology, Federal University of Espirito Santo Brazil.
FAU - Rangel, Leticia Batista Azevedo
AU  - Rangel LB
AD  - Biotechnology Program/RENORBIO, Federal University of Espirito Santo Brazil ; 
      Department of Pharmaceutical Sciences, Federal University of Espirito Santo 
      Brazil.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131215
PL  - United States
TA  - Int J Clin Exp Pathol
JT  - International journal of clinical and experimental pathology
JID - 101480565
RN  - 0 (Antibodies)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Receptors, Progesterone)
SB  - IM
MH  - Antibodies
MH  - *Antibodies, Monoclonal
MH  - Breast Neoplasms/*metabolism
MH  - Carcinoma/*metabolism
MH  - Female
MH  - Humans
MH  - Immunohistochemistry/*methods
MH  - Receptors, Progesterone/*analysis
MH  - Reproducibility of Results
MH  - Tissue Array Analysis
PMC - PMC3885488
OTO - NOTNLM
OT  - Progesterone receptor
OT  - antibodies
OT  - breast cancer
EDAT- 2014/01/16 06:00
MHDA- 2014/09/06 06:00
PMCR- 2013/12/15
CRDT- 2014/01/16 06:00
PHST- 2013/09/25 00:00 [received]
PHST- 2013/10/15 00:00 [accepted]
PHST- 2014/01/16 06:00 [entrez]
PHST- 2014/01/16 06:00 [pubmed]
PHST- 2014/09/06 06:00 [medline]
PHST- 2013/12/15 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Pathol. 2013 Dec 15;7(1):331-9. eCollection 2014.